We read with interest the paper by Crocq et all who reported an association between schizophrenia and homozygosity of a polymorphic site in the first exon of the dopamine D3 receptor gene. The polymorphic site which gives rise to a glycine to serine substitution in the N-terminal extracellular domain of the protein was investigated in two independent samples of patients and controls from France and the UK. After pooling the results of both studies the overall relative risk was 2 61 for schizophrenia in homozygotes.
LETTERS TO THE EDITOR
Excess of homozygosity at the dopamine D3 receptor gene in schizophrenia not confirmed
We read with interest the paper by Crocq et all who reported an association between schizophrenia and homozygosity of a polymorphic site in the first exon of the dopamine D3 receptor gene. The polymorphic site which gives rise to a glycine to serine substitution in the N-terminal extracellular domain of the protein was investigated in two independent samples of patients and controls from France and the UK. After pooling the results of both studies the overall relative risk was 2 61 for schizophrenia in homozygotes.
As noted by the authors, we have studied this polymorphism in an independent series of schizophrenic patients (n = 60) of German origin and also observed a mild but not statistically significant trend towards an overrepresentation of homozygotes ( Finally, it should be noted that the genotype distribution in the French and the UK control samples showed an overrepresentation of heterozygotes which, in addition to the excess of homozygotes in the patients, accounts for the observed relative risk. In the French control group this deviation from Hardy-Weinberg equilibrium was significant (X2=5 47, df=1, p=0019). Although our controls did not show a similar deviation from Hardy-Weinberg equilibrium, the significant overrepresentation of heterozygotes in the healthy controls from France, and to a lesser extent also in the UK controls, is an interesting finding, which might reflect a heterozygote advantage.
In the view of (1) our failure to replicate the finding of an association between schizophrenia and homozygosity at the dopamine D3 receptor gene and (2) the finding of an overrepresentation of heterozygotes in the control groups studied by Crocq et al,' it will be necessary to attempt replication in independent samples of patients as well as in well characterised controls deriving from the same ethnic populations where the initial positive findings were obtained. nificant excess in homozygosity among schizophrenics for a polymorphism in exon 1 of the dopamine D3 receptor gene. They offered two possible explanations for this observation: (1) that the deviation from Hardy-Weinberg equilibrium among the affected population is the result of assortative mating; (2) that the excess of homozygotes among patients reflects heterozygote advantage. The authors favour the second explanation for reasons they discuss in the paper. I would like to offer a third: (3) that there is an excess of persons hemizygous for the dopamine D3 receptor gene markers among the patient population surveyed. The assay that the authors used relies on the ability to PCR amplify the first exon, and then resolve restriction fragments of the amplified DNA on an agarose gel. However, subjects who lack one or more of the PCR primer sites owing to a point mutation or deletion of one allele would be misclassified as homozygous for the other allele in this system. This phenomenon is known as allelic dropout, and it is one of the pitfalls of PCR genotyping, especially when assaying candidate genes for mutant alleles. A similar situation was described by Fujimura et al' when typing for alleles of cystic fibrosis by PCR.
The hypothesis of allelic dropout has several advantages in explaining the observation of Crocq et al. It accounts for why there should be an excess of either of the homozygotes among the affected population. It also does not require that various unspecified mutant alleles be in linkage disequilibrium with two different polymorphisms at the locus, nor does it require that there be a functionally significant polymorphism among the dopamine D3 receptor gene products. I strongly encourage them to assay their patients for changes either in the primer sequences or in copy number at the dopamine D3 receptor locus. ROBERT 
